Targeted therapies, immuno-oncology, and precision medicine programs developed through Zenth Health Sciences' integrated discovery platform. Focused on unmet needs in solid tumors, hematological malignancies, and molecularly defined cancers.
Our integrated approach combines AI-driven target validation, multi-omics patient stratification, and next-generation delivery systems to accelerate translational oncology.
Pan-cancer genomic, transcriptomic, and proteomic profiling to identify biomarker-driven cohorts and precision endpoints.
Proprietary machine learning models trained on 12M+ clinical and preclinical datasets to predict drug-disease interactions and resistance mechanisms.
Lipid nanoparticle and antibody-drug conjugate platforms designed to overcome blood-tumor barriers and reduce off-target toxicity.
Patient-derived xenograft and 3D organoid screening pipelines enabling rapid go/no-go decisions before clinical initiation.